GHK-Cu + KPV Blend
GHK-Cu for skin and collagen with a fixed KPV chaser to keep the site from staying inflamed. One daily shot, 8 to 16 weeks or longer.
What it is
This is the vial for people whose main goal is skin, scars or slow-healing tissue, with a side of inflammation they want quieter: rosacea-prone skin, a surgical scar that stays red, eczema that flares, a gut that is a bit touchy. GHK-Cu does the rebuilding, KPV keeps the swelling and redness from stalling it.
The GHK-Cu half, 50 of the 60 mg, is the part most people are buying. It is a copper-carrying three-amino-acid peptide your body makes and makes less of after 40, and it switches on collagen, elastin and repair genes while carrying copper to where it is used. The KPV half, 10 mg, is the active tail of the hormone alpha-MSH, and its only job is to turn down inflammation signalling. The 5:1 ratio is not magic; it is simply that a normal GHK-Cu dose of 2 mg brings along 400 mcg of KPV, which is squarely in KPV's own working range. The blend exists so a normal dose of one is automatically a normal dose of the other.
Skin responses are slow and cumulative. People notice their skin is less reactive and redness settles in the first two weeks, which is the KPV; firmness, texture and scar colour change over four to eight weeks, which is the GHK-Cu. Hair and nails, if they respond at all, take months. It does nothing for a tendon or a joint, and injected GHK-Cu alone will not replace a retinoid or sunscreen for photoaged skin.
Standard is 2000 mcg GHK-Cu plus 400 mcg KPV once a day subQ, which is 12 units on an insulin syringe after mixing with 3 ml. The solution goes blue; that is the copper, not a problem. It stings more than most peptides and can leave a faint blue-green mark for a day or two, so rotate sites and inject slowly; injecting near a scar is reasonable, near the face is not. Run it 8 to 16 weeks, longer while skin is still improving. There is no set break: neither peptide is known to lose its effect with daily use, and the copper in a normal GHK-Cu dose is far below the daily upper limit for copper; a few weeks off now and then shows what holds, but the blend does not need it. A 60 mg vial is 25 doses at standard, just short of four weeks, so an 8 to 16 week run takes three to five vials. The common mistake is buying the 110 mg vial and assuming the ratio is the same (it is 10:1, with the same 10 mg of KPV).
The evidence is lopsided. GHK-Cu has decades of research and real human trials for skin firmness, wrinkles and wound healing, almost all of it topical rather than injected. KPV has convincing animal work on colitis and skin inflammation and very little in people. The blend has never been tested at all; its case is that the two mechanisms are complementary and do not conflict. Also worth knowing: injectable GHK-Cu is not on the list of substances US compounding pharmacies may use (the FDA took it off its safety-risk list in April 2026 but has not added it to that list), which does not change the science but does mean it is a research-vendor product for now.
If your goal is purely skin and you have no inflammation problem, plain GHK-Cu is cheaper and simpler. If the problem is the gut more than the skin, the BPC-157 + KPV blend fits better. If it is a tendon, joint or a real injury, this is the wrong vial; KLOW adds BPC-157 and TB-500 to this exact pairing for that reason. Skip it if you have Wilson's disease or any copper-handling problem, and skip it with current or past cancer, because GHK-Cu promotes new blood vessel growth.
What people use it for
Skin firmness, wrinkles and scars (GHK-Cu)
Some evidenceGHK-Cu has human trials showing thicker, firmer skin, fewer fine lines and faster wound closure, plus gene-expression work showing it switches on collagen and repair pathways. Nearly all the human data is topical creams, not injections. The injectable logic is that systemic delivery reaches skin everywhere, which is plausible but unproven.
Inflammation of skin and gut (KPV)
Early daysIn mice with colitis and in skin inflammation models, KPV cut the main inflammatory messengers (TNF-alpha, IL-1b, IL-6) and reduced tissue damage. Human data is thin. In practice it is why people with reactive, red-prone skin notice calming in the first fortnight, before any rebuilding shows.
The two together
Early daysNo study has run GHK-Cu and KPV as a pair. The argument is that repair goes badly when inflammation stays high, so calming the site while rebuilding it should help, and nothing suggests the two interfere. Treat it as a reasonable combination of two separately plausible peptides, not a tested product.
What's inside
How it works
- GHK-Cu is well studied for skin, collagen, and wound healing, though mostly topical rather than injected
- KPV calms inflammation convincingly in animal models, with human data still thin
- The blend itself has never been trialed; the case for it is mechanistic
- The fixed 5:1 ratio means a normal GHK-Cu dose also delivers a normal KPV dose
How people use it
Safety, in brief
Things people sometimes notice
- A sharper sting than most peptides, and soreness at the site
- A faint blue-green mark where you injected, from the copper, gone in a day or two
- The mixed solution turning blue, which is normal
- Mild fatigue for a few days when starting
The full picture — stop signs and who should talk to a doctor first — is on the dosing guide.
Sources
This blend's research is on each compound's own page, with its sources: